Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 1Lymphoma, Mantle-Cell 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Classic Follicular Lymphoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 28Cyclophosphamide 14ibrutinib 10Vincristine 10Prednisone 10Doxorubicin 10Bendamustine Hydrochloride 9Radiotherapy 7Peripheral Blood Stem Cell Transplantation 6Filgrastim 6zanubrutinib 5acalabrutinib 4Lenalidomide 4Cyclosporine 4orelabrutinib 3Whole-Body Irradiation 3R-CHOP protocol 3Mycophenolic Acid 3Melphalan 3Interferon-alpha 3Etoposide 3Dexamethasone 3Cytarabine 3Cyclosporins 3venetoclax 2liposomal amphotericin B 2fludarabine phosphate 2fludarabine 2VAP-cyclo protocol 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Mantle-Cell × Hyaluronoglucosaminidase × Clear all
NCT03267433 2026-05-05

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
689 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡